AVITA Medical Inc. (RCEL)
| Bid | 8.77 |
| Market Cap | 232.08M |
| Revenue (ttm) | 53.31M |
| Net Income (ttm) | -41.29M |
| EPS (ttm) | -2.39 |
| PE Ratio (ttm) | -3.68 |
| Forward PE | -9.02 |
| Analyst | Buy |
| Ask | 8.85 |
| Volume | 22,431 |
| Avg. Volume (20D) | 218,903 |
| Open | 9.19 |
| Previous Close | 9.22 |
| Day's Range | 8.79 - 9.18 |
| 52-Week Range | 7.51 - 15.98 |
| Beta | 1.57 |
About RCEL
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a ...
Analyst Forecast
According to 5 analyst ratings, the average rating for RCEL stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 98.75% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago · seekingalpha.com
Investors Burned By AVITA Medical's Sales Miss: I'm Even More BullishAVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance o...
2 months ago · https://thefly.com
Avita Medical price target lowered to $14 from $20 at Lake StreetLake Street analyst Brooks O'Neil lowered the firm's price target on Avita Medical to $14 from $20 and keeps a Buy rating on the shares after the company announced preliminary Q4 commercial revenue th...
